QNCXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 05:00):

Stats
本日の出来高	25 682.00
平均出来高	72 125.00
時価総額	45.59M
EPS	$0 ( 2024-04-02 )
次の収益日	( $0 ) 2024-06-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.260
ATR14	$0.00600 (0.57%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-15	Patni Rajiv	Buy	54 000	Employee Stock Option (right to buy)
2024-02-15	Patni Rajiv	Buy	0
2024-02-01	Ryan Charles S.	Buy	145 000	Employee Stock Option (right to buy)
2024-02-01	Hannah Brendan	Buy	600 000	Employee Stock Option (right to buy)
2024-02-01	Thye Dirk	Buy	1 500 000	Employee Stock Option (right to buy)

INSIDER POWER
90.02
Last 72 transactions
Buy: 5 607 188 \| Sell: 249 899

ボリューム相関

長: -0.04 (neutral)

短: 0.99 (very strong)

Signal:(52.218) Expect same movement, but be aware

Quince Therapeutics, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Quince Therapeutics, Inc. 相関 - 通貨/商品

0.25
( neutral )

0.34
( neutral )

0.00
( neutral )

-0.19
( neutral )

-0.11
( neutral )

Quince Therapeutics, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-322 000 (0.00 %)
EPS:	$-0.840

FY	2023
収益:	$0
総利益:	$-322 000 (0.00 %)
EPS:	$-0.840

FY	2022
収益:	$0
総利益:	$-175 000 (0.00 %)
EPS:	$-1.540

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.02

Financial Reports:

No articles found.

Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.